Skip to content
The Mumbai

Zydus, Formycon Get USFDA Review Acceptance For Keytruda Biosimilar FYB206

Zydus, Formycon Get USFDA Review Acceptance For Keytruda Biosimilar FYB206
Photo: Free Press Journal · view original

Mumbai: Zydus Lifesciences and Formycon AG jointly announced on Monday, 13 October 2026, that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206. FYB206 is a proposed biosimilar to Keytruda (pembrolizumab). Regulatory Acceptance...

Sources and story details